S&P 500   5,103.36 (-0.54%)
DOW   38,799.25 (-0.49%)
QQQ   439.36 (-1.05%)
AAPL   171.20 (-2.23%)
MSFT   409.95 (-1.20%)
META   492.85 (-1.07%)
GOOGL   132.83 (-0.39%)
AMZN   175.73 (-1.04%)
TSLA   182.76 (-2.86%)
NVDA   849.09 (-0.38%)
NIO   5.16 (-3.19%)
AMD   201.31 (-1.97%)
BABA   71.92 (-0.11%)
T   17.14 (+2.02%)
F   12.67 (-0.55%)
MU   94.95 (-0.86%)
CGC   2.96 (-1.99%)
GE   160.99 (-0.01%)
DIS   113.66 (-0.03%)
AMC   4.34 (+0.46%)
PFE   25.83 (-0.23%)
PYPL   60.30 (+0.53%)
XOM   104.89 (+0.51%)
S&P 500   5,103.36 (-0.54%)
DOW   38,799.25 (-0.49%)
QQQ   439.36 (-1.05%)
AAPL   171.20 (-2.23%)
MSFT   409.95 (-1.20%)
META   492.85 (-1.07%)
GOOGL   132.83 (-0.39%)
AMZN   175.73 (-1.04%)
TSLA   182.76 (-2.86%)
NVDA   849.09 (-0.38%)
NIO   5.16 (-3.19%)
AMD   201.31 (-1.97%)
BABA   71.92 (-0.11%)
T   17.14 (+2.02%)
F   12.67 (-0.55%)
MU   94.95 (-0.86%)
CGC   2.96 (-1.99%)
GE   160.99 (-0.01%)
DIS   113.66 (-0.03%)
AMC   4.34 (+0.46%)
PFE   25.83 (-0.23%)
PYPL   60.30 (+0.53%)
XOM   104.89 (+0.51%)
S&P 500   5,103.36 (-0.54%)
DOW   38,799.25 (-0.49%)
QQQ   439.36 (-1.05%)
AAPL   171.20 (-2.23%)
MSFT   409.95 (-1.20%)
META   492.85 (-1.07%)
GOOGL   132.83 (-0.39%)
AMZN   175.73 (-1.04%)
TSLA   182.76 (-2.86%)
NVDA   849.09 (-0.38%)
NIO   5.16 (-3.19%)
AMD   201.31 (-1.97%)
BABA   71.92 (-0.11%)
T   17.14 (+2.02%)
F   12.67 (-0.55%)
MU   94.95 (-0.86%)
CGC   2.96 (-1.99%)
GE   160.99 (-0.01%)
DIS   113.66 (-0.03%)
AMC   4.34 (+0.46%)
PFE   25.83 (-0.23%)
PYPL   60.30 (+0.53%)
XOM   104.89 (+0.51%)
S&P 500   5,103.36 (-0.54%)
DOW   38,799.25 (-0.49%)
QQQ   439.36 (-1.05%)
AAPL   171.20 (-2.23%)
MSFT   409.95 (-1.20%)
META   492.85 (-1.07%)
GOOGL   132.83 (-0.39%)
AMZN   175.73 (-1.04%)
TSLA   182.76 (-2.86%)
NVDA   849.09 (-0.38%)
NIO   5.16 (-3.19%)
AMD   201.31 (-1.97%)
BABA   71.92 (-0.11%)
T   17.14 (+2.02%)
F   12.67 (-0.55%)
MU   94.95 (-0.86%)
CGC   2.96 (-1.99%)
GE   160.99 (-0.01%)
DIS   113.66 (-0.03%)
AMC   4.34 (+0.46%)
PFE   25.83 (-0.23%)
PYPL   60.30 (+0.53%)
XOM   104.89 (+0.51%)
NASDAQ:THMO

ThermoGenesis (THMO) Stock Price, News & Analysis

$0.84
+0.03 (+3.33%)
(As of 09:30 AM ET)
Today's Range
$0.84
$0.84
50-Day Range
$0.37
$1.09
52-Week Range
$0.36
$6.67
Volume
2,407 shs
Average Volume
115,330 shs
Market Capitalization
$2.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

ThermoGenesis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
515.1% Upside
$5.00 Price Target
Short Interest
Healthy
2.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.79mentions of ThermoGenesis in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.35) to $0.08 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.07 out of 5 stars


THMO stock logo

About ThermoGenesis Stock (NASDAQ:THMO)

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.

THMO Stock Price History

THMO Stock News Headlines

ThermoGenesis Holdings, Inc.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
ThermoGenesis Holdings Recent Insider Activity
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
ThermoGenesis Q3 Earnings Preview
Here's what Wall Street expects from ThermoGenesis's earnings report
ThermoGenesis Holdings Inc THMO
ThermoGenesis Holdings Earnings Preview
ThermoGenesis (NASDAQ: THMO)
See More Headlines
Receive THMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ThermoGenesis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/05/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Laboratory apparatus & furniture
Sub-Industry
N/A
Current Symbol
NASDAQ:THMO
Employees
40
Year Founded
1986

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+515.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-11,270,000.00
Net Margins
-148.15%
Pretax Margin
-153.29%

Debt

Sales & Book Value

Annual Sales
$10.48 million
Book Value
$3.20 per share

Miscellaneous

Free Float
690,000
Market Cap
$2.55 million
Optionable
Not Optionable
Beta
2.42

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Xiaochun Xu M.B.A. (Age 53)
    Ph.D., Chairman of the Board & CEO
    Comp: $699k
  • Mr. Jeffery Cauble CPA (Age 51)
    CFO & Corporate Secretary
    Comp: $325k
  • Ms. Haihong Zhu (Age 58)
    COO & Director
    Comp: $554k














THMO Stock Analysis - Frequently Asked Questions

Should I buy or sell ThermoGenesis stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ThermoGenesis in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" THMO shares.
View THMO analyst ratings
or view top-rated stocks.

What is ThermoGenesis' stock price target for 2024?

1 brokerages have issued twelve-month price targets for ThermoGenesis' shares. Their THMO share price targets range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 515.1% from the stock's current price.
View analysts price targets for THMO
or view top-rated stocks among Wall Street analysts.

How have THMO shares performed in 2024?

ThermoGenesis' stock was trading at $0.6010 on January 1st, 2024. Since then, THMO shares have increased by 35.3% and is now trading at $0.8129.
View the best growth stocks for 2024 here
.

Are investors shorting ThermoGenesis?

ThermoGenesis saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 65,400 shares, an increase of 399.2% from the January 31st total of 13,100 shares. Based on an average trading volume of 131,000 shares, the short-interest ratio is presently 0.5 days. Currently, 2.3% of the company's shares are sold short.
View ThermoGenesis' Short Interest
.

When is ThermoGenesis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our THMO earnings forecast
.

How were ThermoGenesis' earnings last quarter?

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) issued its quarterly earnings data on Friday, November, 12th. The company reported ($6.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.60) by $3.15. The business earned $3.16 million during the quarter, compared to the consensus estimate of $3.06 million. ThermoGenesis had a negative net margin of 148.15% and a negative trailing twelve-month return on equity of 402.05%. During the same period in the prior year, the business posted ($16.65) earnings per share.

When did ThermoGenesis' stock split?

ThermoGenesis's stock reverse split on Friday, December 23rd 2022. The 1-45 reverse split was announced on Friday, December 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of ThermoGenesis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ThermoGenesis investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), Co-Diagnostics (CODX), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Pfizer (PFE) and AbbVie (ABBV).

How do I buy shares of ThermoGenesis?

Shares of THMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:THMO) was last updated on 3/5/2024 by MarketBeat.com Staff